AI-generated summary
The authors report a secondary analysis of a sham-controlled trial in 31 people with major depressive disorder who received four near-infrared (808 nm) transcranial photobiomodulation sessions at sham, low, medium, or high doses. They found no statistically significant change in side-effect rates, body weight, or blood pressure across doses. Some individual side effects showed numerical increases that were not statistically significant.
- Participants
- 31
- Who or what was studied
- Adults with major depressive disorder
- Wavelengths
- 808 nm
- Limits stated in the abstract
- The study is a secondary analysis with a small sample of 31 participants, and the abstract reports no significant findings for the dose comparisons.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 808 nm
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Dose, Transcranial photobiomodulation, Randomized controlled trial, Near-infrared, Sham, Dosimetry. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.